• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Eric T. Wong, MD


  • Recht L, Mechtler LL, Wong ET, O'Connor PC, Rodda BE.Steroid-sparing effect of corticorelin acetate in peritumoral cerebral edema is associated with improvement in steroid-induced myopathy.J Clin Oncol. 2013 Mar 20;31(9):1182-7.
  • Drappatz J, Brenner A, Wong ET, Eichler A, Schiff D, Groves MD, Mikkelsen T, Rosenfeld S, Sarantopoulos J, Meyers CA, Fielding RM, Elian K, Wang X, Lawrence B, Shing M, Kelsey S, Castaigne JP, Wen PY.Phase I study of GRN1005 in recurrent malignant glioma.Clin Cancer Res. 2013 Mar 15;19(6):1567-76.
  • Lu R, Wu C, Guo L, Liu Y, Mo W, Wang H, Ding J, Wong ET, Yu M.The role of brevican in glioma: promoting tumor cell motility in vitro and in vivo.BMC Cancer. 2012;12:607.
  • Floyd SR, Kasper EM, Uhlmann EJ, Fonkem E, Wong ET, Mahadevan A.Hypofractionated Radiotherapy and Stereotactic Boost with Concurrent and Adjuvant Temozolamide for Glioblastoma in Good Performance Status Elderly Patients - Early Results of a Phase II Trial.Frontiers In Oncology. 2012;2:122.
  • Fonkem E, Uhlmann EJ, Floyd SR, Mahadevan A, Kasper E, Eton O, Wong ET.Melanoma brain metastasis: overview of current management and emerging targeted therapies.Expert Rev Neurother. 2012 Oct;12(10):1207-15.
  • Fonkem E, Wong ET.NovoTTF-100A: a new treatment modality for recurrent glioblastoma.Expert Rev Neurother. 2012 Aug;12(8):895-9.
  • Stupp R, Wong ET, Kanner AA, Steinberg D, Engelhard H, Heidecke V, Kirson ED, Taillibert S, Liebermann F, DbalĂ˝ V, Ram Z, Villano JL, Rainov N, Weinberg U, Schiff D, Kunschner L, Raizer J, Honnorat J, Sloan A, Malkin M, Landolfi JC, Payer F, Mehdorn M, Weil RJ, Pannullo SC, Westphal M, Smrcka M, Chin L, Kostron H, Hofer S, Bruce J, Cosgrove R, Paleologous N, Palti Y, Gutin PH.NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality.Eur J Cancer. 2012 Sep;48(14):2192-202.
  • Mahadevan A, Floyd S, Wong E, Chen C, Kasper E.Clinical outcome after Hypofractionated Stereotactic Radiotherapy (HSRT) for benign skull base tumors.Comput Aided Surg. 2011 Apr 6.
  • Wong ET, Gautam S, Malchow C, Lun M, Pan E, Brem S.Bevacizumab for recurrent glioblastoma multiforme: a meta-analysis.J Natl Compr Canc Netw. 2011 Apr;9(4):403-7.
  • Lehtinen MK, Zappaterra MW, Chen X, Yang YJ, Hill AD, Lun M, Maynard T, Gonzalez D, Kim S, Ye P, D'Ercole AJ, Wong ET, Lamantia AS, Walsh CA.The cerebrospinal fluid provides a proliferative niche for neural progenitor cells.Neuron. 2011 Mar 10;69(5):893-905.
  • Wong ET, Brem S.Taming glioblastoma by targeting angiogenesis: 3 years later.J Clin Oncol. 2011 Jan 10;29(2):124-6.
  • Drappatz J, Norden AD, Wong ET, Doherty LM, Lafrankie DC, Ciampa A, Kesari S, Sceppa C, Gerard M, Phan P, Schiff D, Batchelor TT, Ligon KL, Young G, Muzikansky A, Weiss SE, Wen PY.Phase I Study of Vandetanib with Radiotherapy and Temozolomide for Newly Diagnosed Glioblastoma.Int J Radiat Oncol Biol Phys. 2010 Sep 1;78(1):85-90.
  • Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM.Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group.J Clin Oncol. 2010 Apr 10;28(11):1963-72.
  • Wong KK, Engelman JA, Cantley LC.Targeting the PI3K signaling pathway in cancer.Curr Opin Genet Dev. 2010 Feb;20(1):87-90. Review.
  • Park S,Zhao D,Hatanpaa KJ,Mickey BE,Saha D,Boothman DA,Story MD,Wong ET,Burma S,Georgescu MM,Rangnekar VM,Chauncey SS,Habib AA.RIP1 activates PI3K-Akt via a dual mechanism involving NF-kappaB-mediated inhibition of the mTOR-S6K-IRS1 negative feedback loop and down-regulation of PTEN.Cancer Res. 2009 May 15;69(10):4107-11.
  • Wong ET,Huberman M,Lu XQ,Mahadevan A.Bevacizumab reverses cerebral radiation necrosis.J Clin Oncol. 2008 Dec 1;26(34):5649-50.
  • Drappatz J,Wong ET,Schiff D,Kesari S,Batchelor TT,Doherty L,Lafrankie DC,Ramakrishna N,Weiss S,Smith ST,Ciampa A,Zimmerman J,Ostrowsky L,David K,Norden A,Barron L,Sceppa C,Black PM,Wen PY.A pilot safety study of lenalidomide and radiotherapy for patients with newly diagnosed glioblastoma multiforme.Int J Radiat Oncol Biol Phys. 2009 Jan 1;73(1):222-7.
  • Lu XQ, Shanmugham LN, Mahadevan A, Nedea E, Stevenson MA, Kaplan I, Wong ET, La Rosa S, Wang F, Berman SM.Organ deformation and dose coverage in robotic respiratory-tracking radiotherapy.Int J Radiat Oncol Biol Phys. 2008 May 1;71(1):281-9.
  • Chowdhary S, Wong ET.Bevacizumab combined with irinotecan for recurrent glioblastoma multiforme--improvement over available therapy?.Nat Clin Pract Neurol. 2008 May;4(5):242-3.
  • Wong ET, Alsop D, Lee D, Tam A, Barron L, Bloom J, Gautam S, Wu JK.Cerebrospinal fluid matrix metalloproteinase-9 increases during treatment of recurrent malignant gliomas.Cerebrospinal Fluid Res. 2008;5:1.
  • Wu WC, Buxton RB, Wong EC.Vascular space occupancy weighted imaging with control of residual blood signal and higher contrast-to-noise ratio.IEEE Trans Med Imaging. 2007 Oct;26(10):1319-27.
  • Wong ET, Brem S.Taming glioblastoma: targeting angiogenesis.J Clin Oncol. 2007 Oct 20;25(30):4705-6.
  • Wong ET, Lee D, Tam A, Gautam S, Wu JK.Matrix metalloprotease-9 in cerebrospinal fluid correlates with disease activity in lymphomatous meningitis.Clin Lymphoma Myeloma. 2007 Jan;7(4):305-8.
  • Wong ET.Is protracted low-dose temozolomide feasible in glioma patients?.Neurology. 2006 Aug 8;67(3):543-4; author reply 543-4.
  • Ramnarain DB, Park S, Lee DY, Hatanpaa KJ, Scoggin SO, Otu H, Libermann TA, Raisanen JM, Ashfaq R, Wong ET, Wu J, Elliott R, Habib AA.Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells.Cancer Res. 2006 Jan 15;66(2):867-74.
  • Wong ET.Tumor growth, invasion, and angiogenesis in malignant gliomas.J Neurooncol. 2006 May;77(3):295-6.
  • Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP, Prados MD, Levin VA, Yung WK.Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials.J Clin Oncol. 1999 Aug;17(8):2572.